Molecular Glues Clinical Pipeline Advances with 90+ Candidates and Emerging Opportunities

Market Summary

The molecular glues clinical trial landscape is evolving rapidly, with more than 80 active companies investigating over 90 pipeline candidates across different stages of development. DelveInsight’s Molecular Glues Competitive Landscape report provides comprehensive insights into emerging therapies, clinical trial progress, competitive strategies, regulatory pathways, and commercial opportunities. The analysis highlights pharmaceutical companies advancing targeted protein degradation and novel molecular interaction approaches to address diseases with limited treatment options.

Explore the Molecular Glues Competitive Landscape to understand pipeline developments, clinical benchmarks, and emerging commercial opportunities : https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Overview of the Molecular Glues Market

Molecular glues are small molecules that induce or stabilize interactions between proteins that would not normally bind effectively. Unlike conventional inhibitors, which block protein activity, molecular glues can redirect cellular machinery to modify protein function or promote the degradation of disease-associated proteins.

Many molecular glue degraders recruit target proteins to E3 ubiquitin ligases, triggering ubiquitination and subsequent destruction through the ubiquitin-proteasome system. This mechanism offers opportunities to address previously difficult-to-target proteins, particularly in oncology, immunology, and other therapeutic areas.

The growing interest in this technology reflects its potential to expand the druggable proteome. However, clinical success will depend on demonstrating safety, selectivity, efficacy, and commercially viable development strategies.

Discover the Molecular Glues in Clinical Trials landscape to explore candidate-specific development progress and competitive positioning : https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Molecular Glues Pipeline Insights

DelveInsight’s report identifies more than 80 companies developing over 90 molecular glue candidates. Approximately seven or more candidates are in late-stage development, while over 15 are progressing through early and mid-stage development.

Key companies include Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, GluBio Therapeutics, Nurix Therapeutics, MindRank, Monte Rosa Therapeutics, SEED Therapeutics, Neomorph, Amphista Therapeutics, Degron Therapeutics, Ambagon Therapeutics, Incyte, BioTheryx, and Amgen.

Emerging mechanisms of action include RAS(ON) inhibition and the degradation of GSPT1, NEK7, SALL4, CK1α, BTK, IKZF1, IKZF3, and c-Myc. These approaches demonstrate the diversity of targets being investigated through molecular glue technologies.

Approved Molecular Glues and Drug Profiles

POMALYST (pomalidomide) and REVLIMID (lenalidomide), marketed by Bristol Myers Squibb, are established examples of immunomodulatory drugs associated with molecular glue activity through cereblon-mediated protein degradation.

POMALYST is indicated for adults with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease has progressed during or shortly after their most recent treatment.

REVLIMID is used across several hematologic malignancies, including multiple myeloma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and myelodysplastic syndromes, according to specific approved indications.

These therapies provide clinical precedent for protein degradation strategies, supporting further investigation of next-generation molecular glues. Nevertheless, individual candidates must establish their own clinical benefits and safety profiles.

Emerging Molecular Glues and Clinical Developments

Several candidates illustrate the breadth of the pipeline. Daraxonrasib, developed by Revolution Medicines, is a late-stage RAS(ON) inhibitor being investigated in oncology. GT919, from Gluetacs Therapeutics, is an oral IKZF1/IKZF3 degrader being evaluated in clinical development. Captor Therapeutics’ CT-01 is being investigated in Phase I, while GLB-001 from GluBio Therapeutics targets CK1α degradation.

Nurix Therapeutics is advancing Zelebrudomide, a dual degrader targeting BTK and cereblon neosubstrates IKZF1 and IKZF3. Meanwhile, MindRank’s MRANK-103 and Monte Rosa Therapeutics’ NEK7-targeting research program represent earlier-stage opportunities.

Recent developments further demonstrate growing research momentum. In April 2026, Monte Rosa Therapeutics presented preclinical findings for MRT-55811, targeting CCNE1-amplified solid tumors. Nested Therapeutics reported initial Phase I results for NST-628, a brain-penetrant, non-degrading pan-RAF/MEK molecular glue.

Amphista Therapeutics presented preclinical findings from its SMARCA2 and TEAD programs, while Neomorph highlighted NEO-811, an ARNT-targeting degrader being developed for clear cell renal cell carcinoma. SEED Therapeutics also advanced its RBM39-targeting research, investigating anticancer activity and potential response biomarkers.

In December 2025, Degron Therapeutics reported first-patient dosing for DEG6498 in a Phase I study, while Gluetacs Therapeutics announced enrollment of the first patient in its Phase II GT919 trial. Other developments included FDA clearance of SEED Therapeutics’ ST-01156 investigational application in August 2025 and Revolution Medicines’ financing and regulatory milestones for its RAS(ON) portfolio in 2025.

Market Outlook and Future Opportunities